Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5
View Patent ↗The present invention is directed to peptides that are capable of blocking the entry of HIV-1 into host cells by means of the CCR5 receptor. The affinity of the peptides for gp120 on the HIV viral surface may be increased by sulfating tyrosine residues. In addition, the invention is directed to a method for increasing the affinity of antibodies for their antigens by sulfating tyrosine residues in the antibody amino acid chain.
1. A peptide 15-30 amino acids in length, comprising at least 15 contiguous amino acids of SEQ ID NO:4, wherein the tyrosine residues at amino acids 19-21 must be present.
2. The peptide of claim 1 , wherein one or more tyrosines in said peptide are sulfated.
3. The peptide of claim 1 , wherein the tyrosine at position 12 of SEQ ID NO:4 is present in said peptide.
4. The peptide of claim 3 , wherein one or more tyrosines at positions 12, 19, 20 or 21 are sulfated.
5. The peptide of claim 4 , wherein at least two tyrosines at positions 12, 19, 20 or 21 are sulfated.
6. The peptide of claim 4 , wherein at least three tyrosines at positions 12, 19, 20 or 21 are sulfated.
7. The peptide of claim 1 , wherein said peptide consists of the amino acid sequence of SEQ ID NO:4, and wherein at least one of the tyrosines at positions 19, 20 or 21 of SEQ ID NO:4 are sulfated.
8. The peptide of claim 1 , wherein said peptide is part of a fusion protein in which said peptide is joined to a sequence that inhibits the interaction between HIV and the CD4 receptor.
9. The peptide of claim 8 , wherein said sequence that inhibits the interaction between HIV and the CD4 receptor is either a virus-binding peptide derived from the CD4 receptor or an antibody blocking CD4/virus binding.
10. The peptide of claim 8 , wherein one or more tyrosines in said peptide are sulfated.
11. The peptide of claim 8 , wherein the tyrosine at position 12 of SEQ ID NO:4 is present in said peptide.
12. The peptide of claim 11 , wherein one or more tyrosines at positions 12, 19, 20 or 21 are sulfated.
13. The peptide of claim 11 , wherein at least two tyrosines at positions 12, 19, 20 or 21 are sulfated.
14. The peptide of claim 11 , wherein at least three tyrosines at positions 12, 19, 20 or 21 are sulfated.
15. The peptide of any one of claims 1 - 14 , wherein said peptide reduces the uptake of an R5 HIV isolate by cultured CCR5-positive immune cells by at least 50% at a concentration of 1 μg/ml.